In This Section      
 

Search Results

A total of 28 matching records were found.

ETCTN10061
A Phase 1 Study of MK-3475 (pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (NCI#10061)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10070
Phase 1/2 study of navitoclax plus vistusertib in patients with relapsed small cell lung cancer (SCLC) and other solid tumors (ETCTN10070)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10131
A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel (ETCTN10131)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10170
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (ETCTN10170)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10204
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) (ETCTN10204)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10214
Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic cancers (ETCTN10214)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN9767
9767 An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1380
A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

J1480
My Pathway: MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS(Protocol Number: ML28897/PRO 02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1705
Study INCB 01158-101 (formerly known as CX-1158-101) Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17121
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination with Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17122
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (CP-MGD013-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17189
J17189-A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1778
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors (sponsor protocol MS100015-0019)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1797
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy (sponsor protocol #SGN22E-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18106
A Phase 1/1b multicenter study to evaluate the humanized anti-CD 73 antibody, CPI-006, as a single agent, or in combination with Ciforadenant with Pembrolizumab, and with Ciforadenant plus pembrolizumab in adult subjects with advanced cancers (CPI-006-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18115
A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors (ASTX727)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18144
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer (FLX475-02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18161
J18161-ADaptiVe Biomarker Trial that InformS Evolution of Therapy (ADVISE)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18180
Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects with Urothelial Carcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1875
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER) (15-1071)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1892
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations (HCRN GU15-262)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1897
Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer (HCRN GU16-287)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19100
A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors with Specific Genomic Aberrations (RMC-4630-02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1956
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors (CA043-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA031501
A031501 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNS1602
S1602 A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore